- Home
- LXRX vs CRDL Comparison
LXRX vs CRDL Comparison
Compare LXRX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CRDL
- Stock Information
- Founded
- LXRX 1995
- CRDL 2017
- Country
- LXRX United States
- CRDL Canada
- Employees
- LXRX N/A
- CRDL N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXRX Health Care
- CRDL Health Care
- Exchange
- LXRX Nasdaq
- CRDL Nasdaq
- Market Cap
- LXRX 124.4M
- CRDL 102.0M
- IPO Year
- LXRX 2000
- CRDL N/A
- Fundamental
- Price
- LXRX $0.46
- CRDL $0.96
- Analyst Decision
- LXRX Buy
- CRDL Strong Buy
- Analyst Count
- LXRX 4
- CRDL 3
- Target Price
- LXRX $3.67
- CRDL $9.00
- AVG Volume (30 Days)
- LXRX 30.7M
- CRDL 241.3K
- Earning Date
- LXRX 03-06-2025
- CRDL 05-13-2025
- Dividend Yield
- LXRX N/A
- CRDL N/A
- EPS Growth
- LXRX N/A
- CRDL N/A
- EPS
- LXRX N/A
- CRDL N/A
- Revenue
- LXRX $31,081,000.00
- CRDL N/A
- Revenue This Year
- LXRX N/A
- CRDL N/A
- Revenue Next Year
- LXRX $101.91
- CRDL N/A
- P/E Ratio
- LXRX N/A
- CRDL N/A
- Revenue Growth
- LXRX 2481.48
- CRDL N/A
- 52 Week Low
- LXRX $0.28
- CRDL $0.88
- 52 Week High
- LXRX $2.45
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- LXRX 50.12
- CRDL 34.30
- Support Level
- LXRX $0.32
- CRDL $1.10
- Resistance Level
- LXRX $0.41
- CRDL $1.18
- Average True Range (ATR)
- LXRX 0.05
- CRDL 0.09
- MACD
- LXRX 0.03
- CRDL -0.01
- Stochastic Oscillator
- LXRX 36.36
- CRDL 22.95
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.